Annual Reports in Medicinal Chemistry

I. Central Nervous System Diseases-Potential CNS Applications for Phosphodiesterase Enzyme Inhibitors (N. J. Brandon and D. P. Rotella)-Recent Developments in Monoamine Reuptake Inhibitors (S. Liu and B. F. Molino)Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease (R. E. Olson and L. R. Marcin)-Recent Advances in Drug Discovery of Histamine H3 Antagonists (R. L. Hudkins, R. Raddatz)-Recent Advances in the Treatment of Insomnia (A. Palomer, M. Princep and A. Guglietta)-Advances in Transient Receptor Potential (TRP) Modulators (A. Vasudevan, M. E. Kort)II. Cardiovascular and Metabolic Diseases-Case History: JANUVIA (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibito for the Treatment of Type 2 Diabetes (A. E. Weber, N. Thornberry)-Cathepsin K Inhibitors (W. Cameron Black and M. David Percival)-New Nonpeptide-Binding GPCRs as Targets for Diabetes and the Metabolic Syndrome (M. C.T.Fyfe, H. A.Overton, M. J.Procter, C. Reynet & J. R. White)-Novel Selective Estrogen Receptor Modulators (SERMS) (J. A. Dodge and T. I. Richardson)-Lipid-metabolizing enzymes as targets for dyslipidemia and insulin resistance (V. Yeh, A. S. Judd, and A. J. Souers)-Recent Trends in HDL Modulating Therapies (D. De and I. Khanna)III. Inflammation / Pulmonary / GastroIntestinal Diseases-Case History on Tegaserod (R. Giger, H. Mattes and H.-J. Pfannkuche)-Advances in the Discovery of CC Chemokine Receptor-2 Atagonists (P. Carter, R. Cherney, I. K.Mangion)-Semicarbazide Sensitive Amine Oxidase and Vascular Adhesion Protein-1: One Protein Being Validated as a Therapeutic Target for Inflammatory Diseases (I. McDonald, J. Foot, P. Yin, E. Flening, E. M. van Dam)-Sphingosine 1-Phospate Type 1 Receptor Modulators: Recent Advances and Therapeutic Potential (N. Cooke and Fr. Zecri)-MAP Kinases Inhibitors in Inflammation and Autoimmune Disorders (S. Bhagwatt)IV. Cancer and Infectious Diseases-Recent Progress on Novel HCV Inhibitors (C. W. Zapf, J. D. Bloom and J. I. Levin)-Small Molecule CCR5 and CXCR4 Based Viral Entry Inhibitors for anti-HIV therapy currently in development (W. W. Kazmierski, K. S. Gudmundsson and S. C. Piscitelli)-Small-molecule inhibitors of Gluthathione S-Transferase P1-1 as anticancer therapeutic agents. (G. Morales and E. Laborde)-Recent Advances in the Medicinal Chemistry of Histone Deacetylase Inhibitors (D. Brittain, H. Weinmann and E. Ottow)-New Developments in Antibacterial Drug R&D (R. Frechette)-Small Molecule Inhibitors of AKT/PKB Kinase As A Strategy for Treating Cancer (D. A. Heerding, I. G. Safonov and S. K. Verma)V. Topics in BiologySpleen Tyrosine Kinase (Syk) Biology, Inhibitors and Therapeutic Applications (R. Singh, E. Masuda)-Systems Biology and Kinase Signaling (B. Gomes and D. de Graaf)-The Molecular Libraries Screening Center Network (MLSCN): Identifying Chemical Probes of Biological Systems (D. M. Huryn and N. D.P. Cosford)-The Application of Transcriptional Profiling in Model Connectivity and Lead Assessment in Drug Discovery (M. Neubauer and P. Ross-Macdonald)VI. Topics in Drug Design and Discovery-Fragment-based lead discovery (M. Congreve, C. W. Murray, R. Carr and D. C. Rees)-Computational Models for ADME (W. J. Egan)-Prediction of human volume of distribution using in vivo, in vitro, and in silio approaches (R. S. Obach)Plasma Protein Binding and the Free Drug Principle: Recent Developments and Applications (G. Trainer)To Market, To Market 2006 (S. Hegde & M. Schmidt)